Genetic Study of Peginterferon Treatment in Hepatitis B Patients: The GIANT-B Study

Inclusion Criteria

• •History of chronic hepatitis B, defined as the presence of positive hepatitis B surface antigen (HBsAg) for at least 6 months.
• •History of treatment (per protocol or outside studies) with standard interferon (alfa-2a or alfa-2b), peginterferon alfa-2a or peginterferon alfa-2b for at least 12 weeks.
• •A follow-up duration of at least 24 weeks after the last dose of (peg)interferon.
• •Use of nucleos(t)ide analogues prior to or combined with (peg)interferon treatment is allowed.
• •Available HBV DNA and HBeAg status at baseline, end of treatment and end of follow-up (24 weeks after end of treatment)
• •Written informed consent obtained.